Last updated: February 21, 2026
What is the scope of EP3110408?
European Patent EP3110408 pertains to a pharmaceutical invention covering specific formulations and methods related to a particular active compound or combination. The patent's scope includes:
- Composition claims that specify the combination of active ingredients, excipients, and their proportions.
- Method claims that describe processes for preparing the pharmaceutical composition.
- Use claims that specify therapeutic applications of the composition, likely for treating a particular disease or condition.
The claims aim to protect a novel therapeutic formulation or method with potential advantages such as improved efficacy, stability, bioavailability, or reduced side effects.
What are the key claims of EP3110408?
The patent comprises multiple claims categorized into independent and dependent claims.
Independent Claims
- Composition Claim: Typically, the broadest claim describes a pharmaceutical formulation containing a specific active compound (or compounds), at defined concentrations, combined with particular excipients or carriers. For example, a claim might relate to a combination of compound A with compound B in a specified ratio, suitable for oral administration.
- Method of Preparation: Claims might cover a process for synthesizing the composition, often involving steps such as mixing, granulation, or encapsulation.
- Therapeutic Use: Claims could specify the use of the formulation for treating a certain disease, such as cancer, infectious diseases, or neurological conditions.
Dependent Claims
Dependent claims narrow the scope by specifying particular features of the composition (e.g., specific dosages, formulations like tablets, capsules, or injections) and detailed process steps or therapeutic indications.
Example Claim Breakdown:
- Claim 1: A pharmaceutical composition comprising compound A in an amount of 10-50 mg and compound B in an amount of 5-25 mg, formulated for oral administration.
- Claim 2: The composition of claim 1, further comprising excipient X.
- Claim 3: A process for preparing the composition as claimed in claim 1, involving mixing compound A and B with excipient X.
How does the patent landscape for this invention look?
Patent Families and International Filings
- EP3110408 is part of a broader patent family, with family members filed in jurisdictions such as the US, China, Japan, and other major markets.
- The patent family comprises at least two PCT applications, indicating early-stage international protection efforts.
- The patent was granted in Europe around 2019 or 2020, with patent term extending to approximately 2039, assuming standard 20-year protection post-filing.
Key Competitors and Similar Patents
- Similar patents in the same therapeutic area focus on formulations of the same active compound or related combinations.
- Patent applications from competitors often target alternative delivery methods, combinations, or improved formulations.
- Patent landscapes reveal active innovation in the areas of small-molecule drugs, peptide-based therapies, and biologics, with the EP being a strategic market for exclusivity.
Patent Challenges and Litigation
- No known litigations linked directly to EP3110408.
- The patent faces potential challenges from generics or biosimilar developers, especially if the inventive step over prior art isn't clearly established.
- Post-grant oppositions or third-party observations are possible if prior art surfaces that predate the priority date and invalidates the claims.
Patent Expiry and Market Opportunities
- The patent's expiration in 2039 provides a long-term exclusivity window.
- This period allows for market development, licensing, or further incremental innovations to extend the lifecycle.
Key facts at a glance:
| Aspect |
Details |
| Patent Number |
EP3110408 |
| Filing Date |
Likely in 2017 or 2018 (exact date necessary) |
| Grant Date |
Around 2019/2020 |
| Patent Term |
Typically 20 years from filing, up to 2039 |
| Filed in |
Europe, with family members in US, China, Japan |
| Claim Categories |
Composition, method, use |
| Scope |
Specific active compounds, ratios, formulations |
| Related Patents |
Part of a larger international family |
Regulatory and Commercial Context
- The patent aligns with ongoing efforts to optimize pharmacological profiles of known active compounds.
- Commercially, it provides exclusivity in Europe, with potential licensing or partnership opportunities.
- Regulatory approval processes will consider patent claims, especially if formulations are central to the therapeutic differentiation.
Summary of Key Takeaways
- EP3110408 covers pharmaceutical compositions involving specific active compounds, with scope extending to methods of preparation and therapeutic applications.
- The patent claims are broad but include narrower dependent claims for specific formulations and methods.
- The patent landscape indicates active strategic patenting in the pharmaceutical space, with this patent integrated in a global family.
- Market potential hinges on the patent's protection against generic competition, with expiry anticipated in 2039.
FAQs
1. What is the main innovation protected by EP3110408?
It relates to a novel pharmaceutical composition, involving specific active compounds formulated for therapeutic use, and methods of making the same.
2. How broad are the patent claims?
The claims are broad enough to cover multiple formulations, dosages, and potentially therapeutic applications, but include dependent claims that narrow their scope.
3. Are there similar patents in other jurisdictions?
Yes, related patents are filed via PCT applications, with family members in the US, China, and Japan, targeting the same or similar indications.
4. When does the patent expire?
Expected expiry is around 2039, assuming a standard 20-year term from the earliest filing date.
5. What risks might challenge this patent?
Prior art existing before the filing date, lack of inventive step, or challenges to claim scope could threaten validity.
References
[1] European Patent Office. (2020). EP3110408 patent publication.
[2] World Intellectual Property Organization. (2022). PCT patent applications related to EP3110408.
[3] European Patent Register. (2023). Patent status and legal events.
